Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) recorded a trading volume of 5.46 million shares, above its 90-day volume average of 0.74 million shares. The stock kicked off the session at $14.3 and later approached $14.95 with a change of 5.28%.Sucampo Pharmaceuticals, Inc. (SCMP) Analyst Opinion
Sucampo Pharmaceuticals, Inc. has a consensus outperform rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 15.6% of shares outstanding. The stock spiked 39.72% last month and is up 10.33 this year. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover SCMP having a buy-equivalent rating. Analysts have placed a $14.13 price target on Sucampo Pharmaceuticals, Inc., suggesting a -5.48% decline from recent close. It’s currently trading about -13.28% below its 52-week high.
Sucampo Pharmaceuticals, Inc. (SCMP) surprised the stock market in its last reported earnings when it earned $0.27 a piece versus the consensus-estimated $0.25. Its revenue totaled $58.05 million down -3.09% from the previous quarter.Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Intraday View
This stock (SCMP) is ahead of its 52-week low with 60.75%. Its last month’s stock price volatility remained 9.05% which for the week stands at 5.03%. The share price has moved forward from its 20 days moving average, trading at a distance of 34.14% and stays 39.19% away from its 50 days moving average. Over the last five days, shares have managed 23.55% gains and now is up 38.9% since hitting its 200-day moving average of $10.82. Sucampo Pharmaceuticals, Inc. (SCMP) has made its way to a 12-month decline of -5.38%.
Turning to Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), its shares were trading at $11.56 a retreat of $-1.45, on the trading floor. The stock, after opening at $12.95, touched a high of $13.086 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.3. Zynerba Pharmaceuticals, Inc. has 1 buy ratings, 3 holds and 0 sells even after the stock tumbled -55.45% from its high of $25.95 to a $156.52 million market value through last close.
The company’s consensus rating on Reuter’s scale improved from 2.29 to 2.33 during a month. Analysts set a 12-month price target of $12.33 a share. The target implies a 6.66% spike from where the shares are currently trading. Also, the current price highlights a discount of 73.01% to analysts’ high consensus price target.Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Intraday Trading
The counter witnessed a trading volume of 0.91 million shares versus an average volume of 0.76 million shares during last trading session. Its last month’s stock price volatility remained 9.76% which for the week approaches 9.1%. The lowest price the stock reached in the last trading day was $11.22 and compares with the $5.42 52-week low. The stock recovered 113.28% since its low point and has performed -25.85% year-to-date.